What are the precautions for using filgotinib for special groups (such as the elderly, pregnant women, etc.)?

Filgotinib is an oral JAK1 selective inhibitor, mainly used to treat immune-related diseases such as moderate to severe rheumatoid arthritis. As a targeted drug, filgotinib has a strong immunomodulatory effect and can inhibit inflammatory responses. However, due to its impact on the immune system, certain special groups (such as the elderly, pregnant women, patients with liver and kidney dysfunction, etc.) need special attention when using it. The following are precautions for the use of filgotinib in these special populations.

1. Precautions when using filgotinib in the elderly

The elderly are often accompanied by multiple chronic diseases, such as hypertension, diabetes, etc., and may have complex drug interactions. For elderly patients, the use of filgotinib requires special caution. The main reason is that the immune system function in the elderly group gradually weakens and may be more sensitive to the drug. In addition, the elderly are often accompanied by decreased liver and renal function, and fibrogotinib is mainly metabolized by the liver. Therefore, elderly patients with hepatic and renal insufficiency may need to adjust the dose when using this drug.

Studies have shown that the elderly have poor tolerance to filgotinib, especially when combined with underlying diseases, and may be more susceptible to adverse reactions such as infection and anemia. Therefore, for elderly patients, doctors usually recommend starting with a lower dose and regularly monitoring liver and kidney function and blood routine to ensure that the drug is used within a safe range. If elderly patients show any signs of serious infection, the drug should be discontinued and treated immediately.

2. Contraindications for pregnant and lactating women

Pregnant women are at higher risk when using filgotinib because the drug may have teratogenic effects on the fetus. Although there is currently insufficient clinical data to directly demonstrate the specific effects of filgotinib on the fetus, pregnant women should avoid using filgotinib due to the drug's mechanism and the results of studies with other JAK inhibitors. If pregnant women become pregnant during treatment, they should stop taking the drug immediately and consult their doctor whether other treatment options are needed.

In addition, lactating women need to be cautious when using filgotinib. Figotinib may be excreted into the baby's body through breast milk. Although there is no clear evidence that it is harmful to the baby, considering the potential impact on the immune system, breastfeeding women should consult a professional doctor before using filgotinib. If the therapeutic effect of filgotinib on the mother is important, it may be necessary to consider suspending breastfeeding or choosing an alternative drug.

3. Use in patients with liver and kidney dysfunction

Patients with hepatic impairment require special caution when using filgotinib. Figotinib is mainly metabolized by the liver. If the patient has impaired liver function, the metabolism of the drug may be affected, resulting in an increase in the concentration of the drug in the body, thereby increasing the risk of adverse reactions. Therefore, patients with hepatic insufficiency usually need to adjust the dose under the guidance of a doctor, and in some cases, discontinuation of the drug may even need to be considered.

Patients with renal insufficiency also need to use filgotinib with caution. Although the drug is primarily metabolized by the liver, some of the drug is also excreted through the kidneys. In patients with renal insufficiency, the clearance of the drug may be affected, resulting in increased plasma concentrations and an increased risk of side effects. Before using filgotinib, doctors usually evaluate the patient's kidney function and adjust the dose as needed. This drug may need to be avoided if the patient's kidney function abnormalities are severe.

4. Immunosuppression and risk of infection

Figotinib regulates the immune system by inhibiting the activity ofJAK1 enzyme, which has obvious advantages in the treatment of immune diseases, but it also means that the patient's immune system may be suppressed, thereby increasing the risk of infection. All patients taking filgotinib, especially the elderly, pregnant women, and patients with hepatic and renal impairment, should be closely monitored for symptoms of infection, especially early in the initiation of treatment. If the patient shows any signs of infection, such as fever, cough, urinary tract infection, etc., they need to seek medical treatment promptly and adjust the treatment plan according to the situation.

In addition, long-term use of immunosuppressants may lead to the recurrence of certain latent infections, such as tuberculosis. Therefore, doctors often recommend TB screening before starting treatment and regular monitoring during treatment. For any patient who develops suspected infection, the drug should be discontinued promptly and anti-infective treatment initiated.

5. Drug Interactions

Patients taking filgotinib, especially those with other chronic medical conditions, may be taking multiple medications simultaneously. There may be interactions between filgotinib and certain drugs, affecting the effectiveness of treatment or increasing side effects. For example, filgotinib may interact with certain antifungal drugs, antiviral drugs, immunosuppressants, and certain antihypertensive drugs. Therefore, patients should report all medications they are currently taking to their physician before using filgotinib so that the physician can evaluate drug interactions and make dose adjustments or choose alternative medications if necessary.

Figotinib has shown significant efficacy in the treatment of moderate to severe rheumatoid arthritis and other immune diseases, but its use in special populations (such as the elderly, pregnant women, patients with liver and kidney dysfunction, etc.) requires special caution. These patients may face a higher risk of side effects when using filgotinib, including infections caused by immunosuppression, liver and kidney damage, drug interactions, etc. Therefore, doctors should formulate individualized treatment plans based on the patient's specific conditions and conduct close monitoring during the treatment process to ensure the safety and efficacy of the drug.

Reference materials:https://go.drugbank.com/drugs/DB14845